Immune Escape of Acute Myeloid Leukemia after Transplantation.

Abstract

We discuss the mechanisms of AML immune evasion including loss or downregulation of MHC class I and II, reduced TRAIL receptor expression, inhibitory metabolite production, inhibitory ligand expression, impaired proinflammatory cytokine production, and AML niche alterations.

COI Statement

N. Köhler reports grants from Deutsche Forschungsgemeinschaft during the conduct of the study. R. Zeiser reports personal fees from Novartis, Sanofi, Therakos, Medac, and Neovii outside the submitted work. No disclosures were reported by the other authors.

References:

Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al. . Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry. Transplant Cell Ther 2024;30:917.e1–917.e12.
Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005;17:202–10.
Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. . Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 2019;25:603–11.
Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, et al. . PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 2011;71:5111–22.
Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, et al. . Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8+ T cells during relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2018;24:666–77.

Article info

Journal issue:

Volume: 6
Issue: 3

Doi:

10.1158/2643-3230.BCD-24-0063

More resources:

MedlinePlus Health Information

Medical

Free resource

NCI CPTC Antibody Characterization Program

Research Materials

Free resource

Silverchair Information Systems

Full Text Sources

Paid

Immune Escape of Acute Myeloid Leukemia after Transplantation.

Abstract

COI Statement

References:

Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al. . Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry. Transplant Cell Ther 2024;30:917.e1–917.e12.
Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005;17:202–10.
Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. . Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 2019;25:603–11.
Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, et al. . PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 2011;71:5111–22.
Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, et al. . Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8+ T cells during relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2018;24:666–77.